Fabio Morandi

List of Publications by Year
in descending order

89 papers	3,378 citations	109321 35 h-index	161849 54 g-index
91 all docs	91 docs citations	91 times ranked	4910 citing authors

#	Article	IF	Citations
1	Molecular Determinants of Neuroblastoma. International Journal of Molecular Sciences, 2022, 23, 3751.	4.1	1
2	HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies. International Journal of Molecular Sciences, 2022, 23, 2925.	4.1	19
3	Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future. Vaccines, 2021, 9, 43.	4.4	18
4	Molecular dynamics of targeting CD38 in multiple myeloma. British Journal of Haematology, 2021, 193, 581-591.	2.5	16
5	Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. Cells, 2021, 10, 927.	4.1	8
6	The Key Role of NAD+ in Anti-Tumor Immune Response: An Update. Frontiers in Immunology, 2021, 12, 658263.	4.8	16
7	The Role of Extracellular Vesicles in the Progression of Human Neuroblastoma. International Journal of Molecular Sciences, 2021, 22, 3964.	4.1	11
8	The Olive Leaves Extract Has Anti-Tumor Effects against Neuroblastoma through Inhibition of Cell Proliferation and Induction of Apoptosis. Nutrients, 2021, 13, 2178.	4.1	15
9	Identification of Biochemical and Molecular Markers of Early Aging in Childhood Cancer Survivors. Cancers, 2021, 13, 5214.	3.7	5
10	Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on Î³Î´ T and NK Cells. Cells, 2020, 9, 1757.	4.1	53
11	The Circular Life of Human CD38: From Basic Science to Clinics and Back. Molecules, 2020, 25, 4844.	3.8	17
12	Human Amnion Epithelial Cells Impair T Cell Proliferation: The Role of HLA-G and HLA-E Molecules. Cells, 2020, 9, 2123.	4.1	19
13	CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy. Frontiers in Immunology, 2019, 10, 760.	4.8	56
14	Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells. OncoImmunology, 2019, 8, e1574198.	4.6	29
15	CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies. Cells, 2019, 8, 1527.	4.1	56
16	Ectonucleotidase Expression on Human Amnion Epithelial Cells: Adenosinergic Pathways and Dichotomic Effects on Immune Effector Cell Populations. Journal of Immunology, 2019, 202, 724-735.	0.8	13
17	Functional insights into nucleotide-metabolizing ectoenzymes expressed by bone marrow-resident cells in patients with multiple myeloma. Immunology Letters, 2019, 205, 40-50.	2.5	11
18	Canonical and non-canonical adenosinergic pathways. Immunology Letters, 2019, 205, 25-30.	2.5	48

#	Article	IF	Citations
19	Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD⁺. OncoImmunology, 2018, 7, e1458809.	4.6	59
20	Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model. OncoImmunology, 2018, 7, e1378843.	4.6	88
21	Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma. Journal of Immunology Research, 2018, 2018, 1-12.	2.2	11
22	CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. Frontiers in Immunology, 2018, 9, 2722.	4.8	124
23	The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases. Mediators of Inflammation, 2018, 2018, 1-10.	3.0	38
24	Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma. OncoImmunology, 2018, 7, e1468953.	4.6	9
25	miRNA expression profile of bone marrow resident cells from children with neuroblastoma is not significantly different from that of healthy children. Oncotarget, 2018, 9, 19014-19025.	1.8	2
26	Antibody mimicry, receptors and clinical applications. Human Antibodies, 2017, 25, 75-85.	1.5	15
27	The Role of HLA-Class Ib Molecules in Immune-Related Diseases, Tumors, and Infections 2016. Journal of Immunology Research, 2017, 2017, 1-2.	2.2	11
28	Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma. Oncotarget, 2017, 8, 53194-53209.	1.8	13
29	Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients. Journal of Immunology Research, 2016, 2016, 1-6.	2.2	10
30	Recent Advances in Our Understanding of HLA-G Biology: Lessons from a Wide Spectrum of Human Diseases. Journal of Immunology Research, 2016, 2016, 1-14.	2.2	104
31	CD4⁺CD25^{hi}CD127^{â˜’} Treg and CD4⁺CD45RO⁺CD49b⁺LAG3⁺ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma. OncoImmunology, 2016, 5, e1249553.	4.6	17
32	PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. OncoImmunology, 2016, 5, e1064578.	4.6	91
33	NAD+-Metabolizing Ectoenzymes in Remodeling Tumorâ€“Host Interactions: The Human Myeloma Model. Cells, 2015, 4, 520-537.	4.1	99
34	Expression ofFOXP3,CD14, andARG1in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival. BioMed Research International, 2015, 2015, 1-10.	1.9	6
35	IL-10 and ARG-1 Concentrations in Bone Marrow and Peripheral Blood of Metastatic Neuroblastoma Patients Do Not Associate with Clinical Outcome. Journal of Immunology Research, 2015, 2015, 1-9.	2.2	16
36	Evaluation of bone marrow as a metastatic site of human neuroblastoma. Annals of the New York Academy of Sciences, 2015, 1335, 23-31.	3.8	25

#	Article	IF	Citations
37	CD56brightCD16â˜' NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation. Journal of Immunology, 2015, 195, 965-972.	0.8	111
38	Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Annals of the New York Academy of Sciences, 2015, 1335, 10-22.	3.8	47
39	Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells. Blood, 2015, 126, 1849-1849.	1.4	16
40	Deregulation of focal adhesion pathway mediated by miR-659-3p is implicated in bone marrow infiltration of stage M neuroblastoma patients. Oncotarget, 2015, 6, 13295-13308.	1.8	13
41	A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation. Oncotarget, 2015, 6, 25602-25618.	1.8	79
42	Binding of HLA-G to ITIM-Bearing Ig-like Transcript 2 Receptor Suppresses B Cell Responses. Journal of Immunology, 2014, 192, 1536-1546.	0.8	137
43	IL-27 Driven Upregulation of Surface HLA-E Expression on Monocytes Inhibits IFN-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi mathvariant="bold-italic">Î³</mml:mi></mml:mrow></mml:math>Release by Autologous NK Cells. Journal of Immunology Research, 2014, 2014, 1-7.	2.2	17
44	Interactions between HLA-G and HLA-E in Physiological and Pathological Conditions. Frontiers in Immunology, 2014, 5, 394.	4.8	74
45	The Role of HLA-Class Ib Molecules in Immune-Related Diseases, Tumors, and Infections. Journal of Immunology Research, 2014, 2014, 1-2.	2.2	4
46	IL-27 in Human Secondary Lymphoid Organs Attracts Myeloid Dendritic Cells and Impairs HLA Class Iâ€"Restricted Antigen Presentation. Journal of Immunology, 2014, 192, 2634-2642.	0.8	20
47	The emerging role of soluble HLA-G in the control of chemotaxis. Cytokine and Growth Factor Reviews, 2014, 25, 327-335.	7.2	29
48	Intrathecal Soluble HLA-E Correlates with Disease Activity in Patients with Multiple Sclerosis and may Cooperate with Soluble HLA-G in the Resolution of Neuroinflammation. Journal of NeuroImmune Pharmacology, 2013, 8, 944-955.	4.1	29
49	Mechanisms of the Antitumor Activity of Human Vγ9Vδ2 T Cells in Combination With Zoledronic Acid in a Preclinical Model of Neuroblastoma. Molecular Therapy, 2013, 21, 1034-1043.	8.2	47
50	Plasma Levels of Soluble HLA-E and HLA-F at Diagnosis May Predict Overall Survival of Neuroblastoma Patients. BioMed Research International, 2013, 2013, 1-9.	1.9	30
51	Soluble HLA-G modulates miRNA-210 and miRNA-451 expression in activated CD4+ T lymphocytes. International Immunology, 2013, 25, 279-285.	4.0	10
52	Immunosuppressive Microenvironment in Neuroblastoma. Frontiers in Oncology, 2013, 3, 167.	2.8	61
53	MYCN: from oncoprotein to tumor-associated antigen. Frontiers in Oncology, 2012, 2, 174.	2.8	16
54	Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. Leukemia, 2012, 26, 1365-1374.	7.2	48

#	Article	IF	Citations
55	Ciclesonide modulates in vitro allergen-driven activation of blood mononuclear cells and allergen-specific T-cell blasts. Immunology Letters, 2012, 141, 190-196.	2.5	2
56	Close Interactions between Mesenchymal Stem Cells and Neuroblastoma Cell Lines Lead to Tumor Growth Inhibition. PLoS ONE, 2012, 7, e48654.	2.5	23
57	Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature. Pediatric Blood and Cancer, 2012, 59, 44-51.	1.5	22
58	Human <scp>TCR</scp>Î³Î´⁺<scp>T</scp> cells represent a novel target for <scp>IL</scp>â€27 activity. European Journal of Immunology, 2012, 42, 1547-1552.	2.9	18
59	Bone Marrow-Infiltrating Human Neuroblastoma Cells Express High Levels of Calprotectin and HLA-G Proteins. PLoS ONE, 2012, 7, e29922.	2.5	40
60	Impairment of lung function might be related to IL-10 and IFN-Î³ defective production in allergic children. Immunology Letters, 2011, 140, 104-106.	2.5	5
61	Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells. Blood, 2011, 118, 5840-5850.	1.4	65
62	Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients. Cancer Immunology, Immunotherapy, 2011, 60, 1485-1495.	4.2	21
63	HLA-G in organ transplantation: towards clinical applications. Cellular and Molecular Life Sciences, 2011, 68, 397-404.	5.4	52
64	Emerging topics and new perspectives on HLA-G. Cellular and Molecular Life Sciences, 2011, 68, 433-451.	5.4	69
65	Interleukin-27 and interleukin-23 modulate human plasmacell functions. Journal of Leukocyte Biology, 2011, 89, 729-734.	3.3	40
66	HLA-G and HLA-E in patients with juvenile idiopathic arthritis. Rheumatology, 2011, 50, 966-972.	1.9	38
67	Dexamethasone Prophylaxis in Pediatric Open Heart Surgery Is Associated with Increased Blood Long Pentraxin PTX3: Potential Clinical Implications. Clinical and Developmental Immunology, 2011, 2011, 1-6.	3.3	11
68	Interferonâ€gamma and ILâ€10 may protect from allergic polysensitization in children: preliminary evidence. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 740-742.	5.7	30
69	Subcutaneous and sublingual immunotherapy and T regulatory cells: there is clinical relevance. Clinical and Experimental Allergy, 2010, 40, 1578-1579.	2.9	1
70	Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma. Cancer Research, 2010, 70, 9816-9826.	0.9	65
71	A Novel Mechanism of Soluble HLA-G Mediated Immune Modulation: Downregulation of T Cell Chemokine Receptor Expression and Impairment of Chemotaxis. PLoS ONE, 2010, 5, e11763.	2.5	43
72	CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunology, Immunotherapy, 2008, 57, 541-548.	4.2	50

#	Article	IF	Citations
73	Immunogenicity of Human Mesenchymal Stem Cells in HLA-Class I-Restricted T-Cell Responses Against Viral or Tumor-Associated Antigens. Stem Cells, 2008, 26, 1275-1287.	3.2	134
74	Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma. Cancer Letters, 2008, 261, 235-243.	7.2	26
75	Umbilical Cord Blood Transplantation: Should Perinatal Solid Cancer Become a Matter of Concern?. Journal of the National Cancer Institute, 2008, 100, 1822-1823.	6.3	2
76	Human Neuroblastoma Cells Trigger an Immunosuppressive Program in Monocytes by Stimulating Soluble HLA-G Release. Cancer Research, 2007, 67, 6433-6441.	0.9	100
77	Expression and Functional Analysis of Human Leukocyte Antigen Class I Antigen-Processing Machinery in Medulloblastoma. Cancer Research, 2007, 67, 5471-5478.	0.9	33
78	Soluble HLA-G: Are they clinically relevant?. Seminars in Cancer Biology, 2007, 17, 469-479.	9.6	167
79	Tumor mRNA-Transfected Dendritic Cells Stimulate the Generation of CTL That Recognize Neuroblastoma-Associated Antigens, Kill Tumor Cells: Immunotherapeutic Implications. Neoplasia, 2006, 8, 833-842.	5.3	42
80	T cell mediated immune responses toÂToxoplasmaÂgondii inÂpregnant women with primary toxoplasmosis. Microbes and Infection, 2006, 8, 552-560.	1.9	22
81	Catastrophic relapse of Evans syndrome five years after allogeneic BMT notwithstanding full donor chimerism. Terminal hemolytic-uremic syndrome. Autoimmunity, 2006, 39, 505-511.	2.6	19
82	Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene, 2005, 24, 4634-4644.	5.9	92
83	Altered centrosomes in ataxia-telangiectasia cells and rapamycin-treated Chinese hamster cells. Environmental and Molecular Mutagenesis, 2005, 46, 164-173.	2.2	7
84	Mechanisms of immune evasion of human neuroblastoma. Cancer Letters, 2005, 228, 155-161.	7.2	76
85	Immunogenicity of Human Neuroblastoma. Annals of the New York Academy of Sciences, 2004, 1028, 69-80.	3.8	48
86	Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. Arthritis Research, 2004, 7, R256.	2.0	56
87	Cytokine flexibility of early and differentiated memory T helper cells in juvenile idiopathic arthritis. Journal of Rheumatology, 2004, 31, 2048-54.	2.0	11
88	Levels of soluble CD27 in sera and synovial fluid and its expression on memory T cells in patients with juvenile idiopathic arthritides. Clinical and Experimental Rheumatology, 2002, 20, 863-6.	0.8	10
89	Bone Marrow Infiltration in Neuroblastoma: Characteristics of Infiltrating Cells and Role of the Microenvironment. , 0, , .		0